Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

Novo Nordisk (NVO) wins U.S. FDA nod for its Alhemo injection as a once-daily prophylaxis for bleeding prevention in patients ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Chad Stevens of Newdale, Idaho, is infused with a gene therapy for hemophilia B at the Nebraska Medical Center in mid-October ...

A staff member at the Nebraska Medical Center prepares to infuse Idaho resident Chad Stevens with a gene therapy for ...

Altuviiio (efanesoctocog alfa) may work better than other treatments as a hemophilia A factor replacement therapy, a study ...

Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia ...

Danish pharmaceutical company Novo Nordisk recently announced plans to spend approximately $1.2 billion to build a new ...

By targeting the root cause of various diseases at the cellular or genetic level, these medical breakthroughs help treat (and ...

Dividend-paying stocks provide investors with consistent income in turbulent markets, especially as payouts grow over time.

Cheap stocks are worth considering now due to expected interest rate cuts, potential market rebounds, and substantial upside ...